BR112017026209A2 - fragmentos e variantes de endostatinas para uso no tratamento de fibrose - Google Patents

fragmentos e variantes de endostatinas para uso no tratamento de fibrose

Info

Publication number
BR112017026209A2
BR112017026209A2 BR112017026209A BR112017026209A BR112017026209A2 BR 112017026209 A2 BR112017026209 A2 BR 112017026209A2 BR 112017026209 A BR112017026209 A BR 112017026209A BR 112017026209 A BR112017026209 A BR 112017026209A BR 112017026209 A2 BR112017026209 A2 BR 112017026209A2
Authority
BR
Brazil
Prior art keywords
fibrosis
variants
treatment
endostatin fragments
endostatin
Prior art date
Application number
BR112017026209A
Other languages
English (en)
Portuguese (pt)
Inventor
Feghali-Bostwick Carol
E. Ryan Terence
S. Padgett Hal
Mcgee Matthew
Original Assignee
Ibio, Inc.
Novici Biotech Llc
Musc Foundation For Research Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibio, Inc., Novici Biotech Llc, Musc Foundation For Research Development filed Critical Ibio, Inc.
Publication of BR112017026209A2 publication Critical patent/BR112017026209A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112017026209A 2015-06-05 2016-06-03 fragmentos e variantes de endostatinas para uso no tratamento de fibrose BR112017026209A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US201562257607P 2015-11-19 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Publications (1)

Publication Number Publication Date
BR112017026209A2 true BR112017026209A2 (pt) 2018-11-27

Family

ID=56236074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026209A BR112017026209A2 (pt) 2015-06-05 2016-06-03 fragmentos e variantes de endostatinas para uso no tratamento de fibrose

Country Status (10)

Country Link
US (2) US10844392B2 (enExample)
EP (1) EP3303383A1 (enExample)
JP (2) JP6952685B2 (enExample)
KR (1) KR20180033499A (enExample)
CN (2) CN115925878A (enExample)
AU (2) AU2016270428B2 (enExample)
BR (1) BR112017026209A2 (enExample)
CA (1) CA2988299C (enExample)
WO (1) WO2016197018A1 (enExample)
ZA (1) ZA201708223B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026209A2 (pt) 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose
SG11202101904UA (en) * 2018-09-14 2021-04-29 Univ Leland Stanford Junior Spd-1 variant - fc fusion proteins
WO2021007094A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
US12454551B2 (en) * 2019-07-31 2025-10-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
US20230265407A1 (en) * 2020-07-02 2023-08-24 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JP3039802B2 (ja) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
CA2313705A1 (en) 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
JP2003517280A (ja) 1999-02-05 2003-05-27 トーマス・ジェファーソン・ユニバーシティ トランス相補性システムを用いての植物における生物医学用ペプチド及びタンパク質の生成
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
AU2004209660A1 (en) 2003-02-03 2004-08-19 Fraunhofer Usa, Inc. System for expression of genes in plants
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP2173377B1 (en) * 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
BR112014001268A2 (pt) * 2011-07-19 2017-02-21 Thrasos Innovation Inc peptídeos antifibróticos e seu uso em métodos para tratamento de doenças e distúrbios caracterizados por fibrose
BR112017026209A2 (pt) 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose

Also Published As

Publication number Publication date
CN107849117B (zh) 2022-08-26
AU2021200765A1 (en) 2021-03-04
US10844392B2 (en) 2020-11-24
CA2988299C (en) 2023-10-31
ZA201708223B (en) 2018-11-28
JP7404320B2 (ja) 2023-12-25
US20210108221A1 (en) 2021-04-15
CA2988299A1 (en) 2016-12-08
JP2022002527A (ja) 2022-01-11
JP6952685B2 (ja) 2021-10-20
EP3303383A1 (en) 2018-04-11
US20180179263A1 (en) 2018-06-28
WO2016197018A9 (en) 2017-01-19
AU2016270428A1 (en) 2018-01-25
AU2021200765B2 (en) 2023-04-13
WO2016197018A8 (en) 2017-07-13
CN115925878A (zh) 2023-04-07
AU2016270428B2 (en) 2020-11-26
US11912755B2 (en) 2024-02-27
WO2016197018A1 (en) 2016-12-08
CN107849117A (zh) 2018-03-27
JP2018524019A (ja) 2018-08-30
KR20180033499A (ko) 2018-04-03

Similar Documents

Publication Publication Date Title
FIC20250034I1 (fi) O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola
ZA201900278B (en) Variant adeno-associated viruses and methods of using
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
PT3681872T (pt) Beta-hidroxietilaminas substituídas com heteroarilo para utilização no tratamento de hiperglicemia
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
BR112017026209A2 (pt) fragmentos e variantes de endostatinas para uso no tratamento de fibrose
LT3256218T (lt) Kdm1a inhibitorius ir jo panaudojimas terapijoje
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
GB201511382D0 (en) Novel compounds and their use in therapy
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
ZA202108601B (en) Anti-tnfalpha-antibodies and functional fragments thereof
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
SG11202000029PA (en) Anti-tnfalpha-antibodies and functional fragments thereof
DK3197898T3 (da) Hidtil ukendte imidazopyridazinforbindelser og deres anvendelse
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
SI3337506T1 (sl) Kombinacije in njihove uporabe
IL261261A (en) Antibodies against tnf-alpha and functional fragments thereof
IL261098A (en) Antibodies against tnf-alpha and functional fragments thereof
HUE043586T2 (hu) 2-aril-4-hidroxi-1,3-tiazol származékok, melyek jól használhatók TRPM8 inhibitorként neuralgia, fájdalom, COPD és asztma kezelésében
IL261793A (en) Anti-tnfalpha antibodies and their functional parts
PT3049196T (pt) Produtos residuais tratados, métodos de preparação e utilização dos mesmos
PT3383381T (pt) Composto para uso na prevenção e tratamento de doenças neurodegenerativas
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: IBIO, INC. (US) ; NOVICI BIOTECH LLC (US) ; MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements